Hemsley Kim M, Hopwood John J
Lysosomal Diseases Research Unit, Department of Genetic Medicine, Women's and Children's Hospital, 72 King William Road, North Adelaide, SA 5006, Australia.
Behav Brain Res. 2005 Mar 30;158(2):191-9. doi: 10.1016/j.bbr.2004.08.019.
Mucopolysaccharidosis (MPS) type IIIA or Sanfilippo syndrome is a lysosomal storage disorder characterised by progressive neurological pathology. Patients exhibit aggression, disturbed sleep, hyperactivity and mental decline ultimately resulting in inanition and death. Recently, a mouse model of MPS-IIIA was discovered, and both the clinical signs and neuropathological changes mimic the human disease. This provides us with an opportunity to study the pathological progression of this disorder and to determine the efficacy of novel therapies, for at present all lysosomal storage disorders (LSD) affecting the brain are untreatable. Neuropathological changes have previously been described in areas of the brain involved in regulating motor function, therefore, in the present study we sought to determine whether quantifiable motor abnormalities were present in the MPS-IIIA mouse, and if so, at what age they became detectable. Tests of open-field locomotor activity, hindlimb gait, catalepsy, neuromuscular strength and negative geotaxis were administered to MPS-IIIA and normal male and female mice aged from 3 to 40 weeks of age. Significant changes in open-field activity were observed from 3 weeks in MPS-IIIA mice, whereas abnormalities in tests of gait, grip strength and in the assessment of the negative geotaxis response were observable from approximately 15 weeks of age. Behavioural changes were often detected in male MPS-IIIA mice before they appeared in females. Our observations provide insight into the chronology of pathological changes within the MPS-IIIA brain and this simple series of tests will prove useful in comparing mice following the administration of experimental therapies for this condition.
ⅢA型粘多糖贮积症(MPS)或桑菲利波综合征是一种溶酶体贮积病,其特征为进行性神经病理学改变。患者表现出攻击行为、睡眠障碍、多动和智力衰退,最终导致消瘦和死亡。最近,发现了一种ⅢA型MPS的小鼠模型,其临床症状和神经病理学变化均与人类疾病相似。这为我们提供了一个研究该疾病病理进展以及确定新疗法疗效的机会,因为目前所有影响大脑的溶酶体贮积病(LSD)均无法治疗。此前已在参与调节运动功能的脑区描述了神经病理学变化,因此,在本研究中,我们试图确定ⅢA型MPS小鼠是否存在可量化的运动异常,如果存在,在什么年龄可以检测到。对3至40周龄的ⅢA型MPS小鼠以及正常雄性和雌性小鼠进行旷场运动活动、后肢步态、僵住症、神经肌肉力量和负趋地性测试。ⅢA型MPS小鼠在3周龄时旷场活动就出现了显著变化,而在大约15周龄时可观察到步态、握力测试以及负趋地性反应评估中的异常。行为变化通常在雄性ⅢA型MPS小鼠中比在雌性小鼠中更早出现。我们的观察结果有助于深入了解ⅢA型MPS脑内病理变化的时间顺序,并且这一系列简单测试将证明在比较针对该病症给予实验性治疗后的小鼠时很有用。